Category: Pharmaceutical company
Quick infos Headquarters: Massachusetts, United States Trade prices Volume: Market Cap: 2.58B Prev closed: Open: 38.4 High: 38.4 Low: 36.86 52 week low: 27.12 52 week high: 99.95 Dividends: No Dividends Next ER: November 10, 2021
About the Company Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts which aims to develop therapies based on CRISPRâCas9 gene editing technology. The company went public on 2 Feb 2016.
Earnings History Date EPS / Forecast Revenue / Forecast March 8, 2022 November 10, 2021 - / -0.8093- / 4.68MAugust 4, 2021 -0.81 / -0.8235379K / 6.03MBeat! May 5, 2021 -0.86 / -0.74386.5M / 5.83MBeat! February 25, 2021 -1 / -0.7611.42M / 5.64MBeat! view more
Historical Data Date Price Open High Low Vol Change ER Oct 22, 2021 37.82 38.40 38.40
36.86
864.57K -1.69% Oct 21, 2021 38.47 38.49 39.70
38.40
841.73K 0.16% Oct 20, 2021 38.41 39.50 39.78
38.28
980.59K -2.14% Oct 19, 2021 39.25 38.80 40.25
38.35
1.07M 2.53% Oct 18, 2021 38.28 38.06 38.61
37.40
997.91K 0.68% Oct 15, 2021 38.02 39.39 39.48
37.86
955.91K -2.39% Oct 14, 2021 38.95 38.49 39.70
38.07
1.47M 2.85% Oct 13, 2021 37.87 37.01 38.49
36.74
1.07M 0.91% Oct 12, 2021 37.53 37.06 39.30
37.06
1.87M 2.43% Oct 11, 2021 36.64 35.75 37.28
35.50
1.50M 2.89% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company News
PreMarket Prep Stock Of The Day: Editas Medicine finance.yahoo.com Oct 23, 2021 1:14 pm
Implied Volatility Surging for Editas (EDIT) Stock Options finance.yahoo.com Oct 23, 2021 9:32 am
Editas Medicine to Present at Chardans 5th Annual Genetic Medicines Conference finance.yahoo.com Oct 23, 2021 8:00 am
Buying This Beaten-Down ETF Could Double Your Money Over the Next 5 Years fool.com Oct 23, 2021 5:52 am
Clinical Data from Editas Medicines Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress finance.yahoo.com Oct 20, 2021 9:00 am
Insiders in Editas Medicine, Inc. (NASDAQ:EDIT) are down 18% on their US$1.4m purchase despite recent gains finance.yahoo.com Oct 16, 2021 9:35 am
4 Biotechs to Watch Amid Rising Prominence of Gene Therapies finance.yahoo.com Oct 14, 2021 9:40 am CRISPR draws mixed views from analysts after data for allogeneic CAR-T therapy seekingalpha.com Oct 13, 2021 8:15 pm Intellia Therapeutics slides after insider selling seekingalpha.com Oct 8, 2021 10:56 pm
Editas Medicine to Present Preclinical Data on Novel Engineered iPSC Derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting finance.yahoo.com Oct 7, 2021 8:00 am Atea Pharma, Evolent among weekly healthcare gainers; Omeros, Novavax trail seekingalpha.com Oct 2, 2021 9:20 am Editas Stock Firestorm Rages On; CRISPR Gene-Editing Stock Flashes Sell Signal investors.com Sep 30, 2021 4:02 pm
Breaking Down CRISPR Technology fool.com Sep 28, 2021 6:45 am
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming finance.yahoo.com Sep 10, 2021 7:30 am
Editas Medicine Unveils Preclinical Data From New Gene Editing Technology finance.yahoo.com Sep 10, 2021 6:11 am 3 Red-Hot Healthcare Stocks to Buy in September fool.com Sep 9, 2021 12:37 pm
Initial Clinical Data from Editas Medicines BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September finance.yahoo.com Sep 7, 2021 4:00 pm Editas plunges as Morgan Stanley calls gene editing data “inconclusive” seekingalpha.com Sep 30, 2021 3:38 am ProQR reaches a six month high after Editas data for gene editing candidate seekingalpha.com Sep 29, 2021 9:57 pm Editas posts preliminary data from early-stage EDIT-101 eye disease trial seekingalpha.com Sep 29, 2021 9:15 pm This company doesn't provide a dividend.
Key Persons Talk about Editas below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon Technical analysis is a collection of techniques designed to help you make trading decisions in securities markets. Technical Analysis For Dummies helps you take a hard-headed look at what securities prices are actually doing rather than what economists or analysts say they should be doing, giving you the know-how to use that data to decide whether to buy or sell individual securities.
A simple, straightforward guide to the fundamentals of technical analysis
